HIGHLIGHTS
- who: Go Okada from the This study will be a non-randomized, open-label study involving patients with MDD and healthy controls (HCs)This trial will be conducted at eight facilities (Hiroshima University Hospital, Kabe Mental Health Clinic, Minna no Suimin Stress Care Clinic, Mantani Mental Clinic, Ujina Mental Clinic, Yokota Mental Clinic, Tamura Mental Clinic, and Jitsuiki Clinic) in Japan. Three groups of patients with MDD will be enrolled in this study. The first group will continue treatment with escitalopram only for at least the first , weeks but will be followed for a total of , months . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.